Pacira reports Q4 adjusted EPS 80c, consensus 83c

Reports Q4 revenue $172M, consensus $173.5M. "2022 was a solid year for Pacira as we posted record revenue and significant adjusted EBITDA, recently surpassed our twelve millionth patient with EXPAREL, and advanced our product portfolio into new and exciting indications," said Dave Stack, chairman and chief executive officer of Pacira BioSciences. "We enter 2023 in a strong position with significant and durable cash flows that we believe will allow us to leverage our balance sheet to self-fund our growth and expansion. In the coming year we expect to achieve a variety of value-driving milestones including growing product revenue, developing new indications for our commercial offering, advancing our clinical pipeline, improving gross margins, increasing cash flow, and pre-paying significant portions of our term loan B debt, which would further strengthen our balance sheet."The need for non-opioid pain management remains a global imperative and our continued progress further solidifies our leadership role in this important work," added Mr. Stack.